Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.

Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ.

Ann Oncol. 2005 Jun;16(6):923-7. Epub 2005 Apr 11.

PMID:
15824080
2.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
3.

Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.

J Thorac Oncol. 2008 Jul;3(7):756-63. doi: 10.1097/JTO.0b013e31817c73d6.

4.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access program investigators.

J Thorac Oncol. 2006 Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621.

5.

Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.

Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.

Respir Investig. 2014 Mar;52(2):101-6. doi: 10.1016/j.resinv.2013.07.002. Epub 2013 Sep 13.

PMID:
24636265
6.

The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.

Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.

J Thorac Oncol. 2006 Jul;1(6):591-601. Review.

7.

Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

Green J, Dundar Y, Dodd S, Dickson R, Walley T.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005574. Review.

PMID:
17253564
8.

[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].

Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Mar;36(3):162-8. Chinese.

PMID:
23856136
9.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.

Lung Cancer. 2012 Sep;77(3):567-71. doi: 10.1016/j.lungcan.2012.05.111. Epub 2012 Jul 4.

PMID:
22770372
10.

Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.

Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M.

Lung Cancer. 2012 Mar;75(3):360-7. doi: 10.1016/j.lungcan.2011.08.011. Epub 2011 Sep 19.

PMID:
21937142
11.

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.

Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA; Pemetrexed Expanded Access Program Investigators.

Lung Cancer. 2007 Feb;55(2):187-94. Epub 2006 Nov 7.

PMID:
17092602
12.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.

Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.

Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17.

13.

Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.

Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.

J Thorac Oncol. 2008 Jul;3(7):764-71. doi: 10.1097/JTO.0b013e31817c73ec.

14.

Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.

Woods B, Paracha N, Scott DA, Thatcher N.

Lung Cancer. 2012 Feb;75(2):261-7. doi: 10.1016/j.lungcan.2011.07.011. Epub 2011 Sep 19.

PMID:
21937141
15.

Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice.

Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J.

Value Health. 2008 Jan-Feb;11(1):4-12. doi: 10.1111/j.1524-4733.2007.00209.x.

16.

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ.

J Clin Oncol. 2009 Jun 20;27(18):3007-13. doi: 10.1200/JCO.2008.20.3943. Epub 2009 Apr 13.

17.

Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.

Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.

Clin Cancer Res. 2009 Jan 1;15(1):382-9. doi: 10.1158/1078-0432.CCR-08-0128.

18.

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.

Clin Cancer Res. 2005 Feb 1;11(3):982-92.

19.

Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.

Habib EE, Fahmy ES.

Clin Transl Oncol. 2013 Nov;15(11):965-8. doi: 10.1007/s12094-013-1015-3. Epub 2013 Feb 14.

PMID:
23408040
20.

Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?

Rusch VW.

J Clin Oncol. 2003 Jul 15;21(14):2629-30. No abstract available.

PMID:
12860935

Supplemental Content

Support Center